• Company established.

• Commenced commercial production.

• Obtained GMP Certificate from NMPA.

• Passed WHO GMP on site inspection(1st time).

• Completed API registrations in Brazil, Russia, South Africa, and other markets.

• Passed WHO GMP inspection (2nd time) and USFDA GMP inspection (1st time)

• Passed USFDA GMP inspection (2nd time).

• Anti-HIV and Anti-HBV drugs took the lead in passing consistency evaluation.

• Passed WHO GMP inspection (3rd time).

• Received CEP Certificate for Lamivudine from the EDQM
• Paroxetine Hydrochloride and Pregabalin passed consistency evaluation
• Founded Subsidiary companies Shandong Sinlink and Shandong Keyzon.

• License granted by the Medicines Patent Pool (MPP) for the production of Molnupiravir API and FDF for COVID‑19 treatment.

• Passed WHO、 GMP inspection (4th time);
• Passed WHO Prequalification and PIC/S、GMP inspection for finished dosage forms.

• Passed USFDA、GMP inspection (3rd time).

• Received CEP Certificate for Esomeprazole Magnesium from EDQM.